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Racemases and epimerases operating through
a 1,1-proton transfer mechanism: reactivity,
mechanism and inhibition
Matthew D. Lloyd, *a Maksims Yevglevskis,ab Amit Nathubhai,ac
Tony D. James, de Michael D. Threadgillaf and Timothy J. Woodmana
Racemases and epimerases catalyse changes in the stereochemical configurations of chiral centres and
are of interest as model enzymes and as biotechnological tools. They also occupy pivotal positions
within metabolic pathways and, hence, many of them are important drug targets. This review
summarises the catalytic mechanisms of PLP-dependent, enolase family and cofactor-independent
racemases and epimerases operating by a deprotonation/reprotonation (1,1-proton transfer) mechanism
and methods for measuring their catalytic activity. Strategies for inhibiting these enzymes are reviewed,
as are specific examples of inhibitors. Rational design of inhibitors based on substrates has been
extensively explored but there is considerable scope for development of transition-state mimics and
covalent inhibitors and for the identification of inhibitors by high-throughput, fragment and virtual
screening approaches. The increasing availability of enzyme structures obtained using X-ray crystallo-
graphy will facilitate development of inhibitors by rational design and fragment screening, whilst protein
models will facilitate development of transition-state mimics.
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Introduction
Chirality is at the very heart of Chemical Biology. Proteins,
nucleic acids, carbohydrates and many lipids are all chiral
molecules, as are the overwhelming majority of their monomer
precursors. In addition, many cellular metabolites also contain
chiral centres. It is well-known that, for most chiral bio-
molecules, one particular configuration is preferred; thus
proteins contain predominantly chiral amino-acids with
L-configuration1,2 (S-configuration in the Cahn-Ingold-Prelog
system3 except for R-cysteine and achiral glycine). Similarly,
carbohydrates are or contain predominantly D-sugars, with
L-ascorbic acid (vitamin C) being a well-known exception.
An important consequence of the chiral nature of proteins is
that, when they interact with other chiral molecules, a diaster-
eomeric situation arises; thus, most proteins will be highly
selective for a particular configuration of their interacting
partners (substrate, inhibitor, allosteric effector). An important
consequence of this is that different stereoisomers of chiral
drugs are effectively different drugs, which will generally have
different protein targets (enzyme, receptors etc.) and different
pharmacokinetics.4,5 Finally, many drugs are known to undergo
metabolic changes of chiral configuration in vivo,4,5 e.g. ibuprofen
and related ‘profens’ (reviewed in ref. 6–8) and mandelic acid.9,10
In addition the 2-(aryloxy)propanoic acid herbicides undergo
changes in chiral configuration which are mediated by soil
bacteria.11–13
Notwithstanding the fact that most biological molecules
exist overwhelmingly in one stereochemical configuration,
there are many examples where minor stereoisomers play an
essential role. The most well-known example of this is proteino-
genic amino-acids such as alanine and glutamate, which are
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found in their D-configuration (R-configuration) within bacterial
peptidoglycan.14–17 In most cases, these minor stereoisomers are
not biosynthesised de novo but are obtained by changing the
stereochemical configuration of the most abundant isomer into
that of the less abundant isomer.
The enzymes which perform these changes in stereochemical
configuration are known as racemases and epimerases, which
have been shown to have a pivotal position in metabolism, and
thus have gained significant interest as drug targets for diseases
such as bacterial infections,14,18–25 Chagas disease,26–28
cancer,6,7,18,29 Alzheimer’s disease and other dementias,1,2,30–32
formation of cataracts1,33 and diabetic retinopathy;34 racemase
levels are also a marker of ischaemic stroke.35 Inhibition of
diaminopimelate epimerase activity also potentiates cephem
antibiotic activity by compromising the integrity of the bacterial
cell wall.36
Low activity or concentrations of racemases/epimerases
(AMACR,37 methylmalonyl-CoA epimerase38) are associated
with inherited errors in metabolism and may also be associated
with stroke and dementia39 and neurodegenerative diseases,40
such as Amyotrophic Lateral Sclerosis (ALS, a.k.a. motor neu-
rone disease, Lou Gehrig’s disease). Increased methylmalonic
acid levels in the aging population (resulting from a decrease
in methylmalonyl-CoA epimerase activity) is suggested to
promote an aggressive cancer phenotype by upregulation of
the SOX4 transcription factor.41 Increased levels of aspartate/
glutamate racemases protect Salmonella enterica from amino-
acrylate metabolic stress.42 Increased activity of the bifunctional
enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannos-
amine kinase results in sialuria, an extremely rare genetic
disorder, while knockout of the corresponding gene is lethal in
mice.43,44 Mutations in this epimerase are linked to hereditary
inclusion body myopathy (HIBM).44,45 In addition, O-ureidoserine
racemase is involved in the biosynthesis of the antibiotic D-cyclo-
serine,46 while a peptide epimerase is found in funnel web spider
(Agelenopsis aperta) venom which interconverts two 48 amino-
acid peptides differing only in the configuration at a single
serine residue (Ser-46).47 Finally, racemases and epimerases are
used in dynamic kinetic resolutions and other biotechnological
applications.48–54
Racemases and epimerases use several different strategies to
bring about changes in stereochemical configuration of their
substrates, including the use of radical reactions,55–60 elimina-
tion and re-addition of nucleotides20,61 and the use of redox
cofactors.18,19,62–64 An important example of a ‘epimerase’
utilising redox cofactors is decaprenylphosphoryl-b-D-ribose
epimerase (DprE); however, this is not a true epimerase reac-
tion as the oxidative and reductive reactions are catalysed by
separate enzymes (DprE1 and 2, respectively) using different
cofactors [flavin adenine dinucleotide (oxidised) and nicotina-
mide adenine dinucleotide (reduced)].65–68
By far the most common mechanism used by racemases and
epimerases is the deprotonation/reprotonation14,18,20,63 (1,1-
proton transfer) reaction. These enzymes fall into three classes:
those which are pyridoxal 50-phosphate (PLP)-dependent;5,50,69,70
those which use metal ions (enolase enzymes14,49,71,72); and
those which are cofactor-independent (Scheme 1).6,7,18,20,63
The PLP-dependent enzymes (Scheme 1A) catalyse exchange
between PLP in the internal aldimine 1 (catalytic Lys side-
chain) and the external aldimine 2 (substrate a-amino group).
Deprotonation69,70 of 2 results in the ylide intermediate 3
which is subsequently reprotonated from the other face to
produce the external aldimine 4 with opposite configuration.
In contrast, the metal-dependent enzymes, e.g. mandelate racemase,
apparently perform a concerted reaction (Scheme 1B; 5–7).
Solvent isotope experiments show that label is incorporated into
product with little incorporation into recovered substrate,73,74
which is consistent with a concerted mechanism. However,
kinetic isotope effect measurements on mandelate racemase are
consistent with a stepwise reaction and a discrete deprotonated
intermediate.75 Finally, most cofactor-independent racemases/
epimerases utilise a concerted mechanism,5,76–78 as illustrated
by glutamate racemase (Scheme 1C; 8–10). However, some
cofactor-independent enzymes using substrates with acidic
a-protons perform their reactions with a stepwise mechanism
via a discrete enolate intermediate (e.g. a-methylacyl-CoA
racemase79–81).
Enzymes which use metal ions as Lewis acids (enolase
family enzymes) or are cofactor-independent are of particular
interest, since they are able to perform the apparently simple
1,1-proton transfer using active site amino-acid residues and
thus are model systems for understanding enzymatic reactions
in general. Several of these enzymes are also important as drug
targets,6,7,20–23 potential drug targets,84 or are used in biotechno-
logical applications.48,49,51 This review will consider racemases/
epimerases utilising deprotonation and deprotonation mechanisms,
their reactivity and the strategies used to inhibit them.
Reactivity of racemases and
epimerases
Racemisation and epimerisation reactions
On the face of it, the reaction catalysed by racemases and
epimerases operating through a 1,1-proton transfer mechanism
is deceptively simple, consisting of only deprotonation and
deprotonation (Scheme 1). In the case of the PLP-dependent
enzymes, e.g. alanine racemase, the active site is situated at the
interface between two dimer subunits.69 Formation of the
external aldimine between the PLP cofactor and substrate
considerably enhances the acidity of the Ca–H.
5,18,20,69 Stabili-
sation of the developing negative charge in PLP-dependent
enzyme reactions requires that the broken bond is perpendi-
cular to the PLP p-system.69,70,85
The imine nitrogen between the amino-acid substrate and
the PLP cofactor is thought to be protonated5 and this
enhances the acidity of the Ca–H. This effect is illustrated by
chemical systems which show that the pKa of zwitterionic
glycine is 28.9 whilst the corresponding pKa for the zwitterionic
imine between glycine and acetone is 22.86 Model studies using
the glycine aldimine of pyridoxal suggest a Ca–H pKa value of
11 and 17 for when the pyridoxal aromatic hydroxy group is
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protonated and deprotonated, respectively.5 These studies also
show that protonation of the amino-acid carboxylate further
decreases the Ca–H pKa value to 6 but crystal structures suggest
that this does not occur during the enzyme catalytic cycle. This
is contrast to the situation in cofactor-independent racemases/
epimerases, where substrate carboxylate groups are held within
a hydrogen-bonding network20 or transiently protonated during
the reaction.21 The pKa of the external aldimine Ca–H in the
alanine racemase reaction is estimated to be 9, which is
intermediate between those for the catalytic bases, Tyr-265
and Lys-39.69
The mechanism of some PLP-dependent enzymes, e.g.
ornithine decarboxylase, is thought to go via a quinoid
intermediate69,70 resulting from protonation of the pyridoxal
nitrogen by a glutamic acid residue. The equivalent residue in
alanine racemase is an arginine and the pyridoxal nitrogen is
not extensively protonated69,70 (Scheme 2). Therefore, alanine
racemase is thought to catalyse its reaction via a carbanion 3
not a quinoid 11 intermediate.69 Kinetic isotope effect experi-
ments on alanine racemase are consistent with a carbanion
rather than quinoid intermediate.70,87
The situation is different for enolase-family racemases and
epimerases and those which are cofactor-independent. The
fundamental problem for these enzymes is how to deprotonate
a substrate carbon acid (typical pKa = B21–23
86,88,89) using
active site bases with pKa values in the range 6–9 without the
enhancement afforded by a PLP cofactor. Many racemase/
epimerase substrates possess carboxylic acids (pKa 2–5),
which are deprotonated to the negatively charged carboxylate
(e.g. substrates of amino-acid racemases/epimerases20 and
methylmalonyl-CoA epimerase90). Consequently, the apparent
pKa of the Ca–H for these substrates will be B29.
20,86 This effect
is illustrated by chemical systems, which show that the pKa for
the Ca–H of glycine in water is 28.9, while the corresponding
pKa for glycine methyl ester is 21.0.
86
Racemases and epimerases utilising a negatively charged
substrate generally hold the carboxylate group within a
hydrogen-bonding network or ion pair to disperse the negative
charge.20 In some cases, the enzyme also transfers the incoming
proton onto the substrate carboxylate group before it is trans-
ferred onto the Ca of the product (e.g. glutamate racemase
21).
Scheme 2 Carbanion 3 and quinoid 11 intermediates in the alanine
racemase reaction.69
Scheme 1 Example mechanisms of racemases and epimerases operating
by a 1,1-proton transfer mechanism. (A) PLP-dependent amino acid
racemases, as shown by alanine racemase;5,69 (B) Metal-dependent (eno-
lase) enzymes, as shown by mandelate racemase;74,75 (C) Cofactor-
independent racemases as shown by glutamate racemase.63,82,83 Dashed
lines show bonds being broken or formed in the transition state.
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Exceptions to this strategy are seen with methylmalonyl-CoA
epimerase90 and mandelate racemase,91,92 where the carboxylate
group is ligated to the active site Co2+ or Mg2+ ion which acts as
a Lewis acid and diminishes the pKa of the Ca–H.
21 Typically
the carboxylate group is also held within a hydrogen-bonding
network with active-site residues.5 Some racemase/epimerase
substrates also contain further destabilising groups, such as
ammonium groups (amino-acid racemases/epimerases),18,20
amide carbonyl groups (N-succinylamino acid racemases, dipep-
tide epimerases and other enolase family enzymes18,49) and OH
(mandelate racemase,18,91 various sugar epimerases18). Both
ammonium and OH groups are more easily deprotonated than
the Ca–H. Chemical models
86,93 show that the pKa of the Ca–H is
diminished by 9–15 units by protonation of an adjacent amine
and a number of amino-acid racemases/epimerases,20,94 including
diaminopimelate epimerase and glutamate racemase, appear
to protonate the amine of the substrate during the reaction.
In the case of mandelate racemase18,91 and N-succinylamino-
acid racemases,49 the OH or amide carbonyl groups are ligated
to active-site metals such as Mg2+ (mandelate racemase18,91,92)
or Co2+, Mn2+ or, occasionally, Mg2+ (N-succinylamino-acid
racemases49). The rates of proton transfer for the deprotonation
and reprotonation steps are generally high, with rate constants
of the order of 5  109 to 100  109 M1 s1.86
Recent analysis18 of racemase/epimerase crystal structures,
obtained in the presence of ligands, suggests that the vast
majority of enzymes bind the two substrate stereoisomers using
‘mirror-image packing’, that is functional groups are held
within the same position with the Ca–H on opposite sides in
the different stereoisomers. In some cases, e.g. amino-acid
racemases/epimerases,20 the positions of the substrate side-
chain and functional groups show remarkably small differ-
ences in their positions between the stereoisomers. In other
cases, e.g. AMACR/MCR6,7,18,95 which utilises substrates with
large hydrophobic side-chains, the different epimers are
accommodated by fixing two of the function groups (the methyl
group and acyl-CoA moiety in this case) whilst the side-chain is
accommodated in discrete binding sites on a hydrophobic
surface at the entrance of the active site.
The active-site bases sit immediately adjacent to the Ca–H.
In the vast majority of cases, the active-site bases are located on
both sides of the substrate (the so called ‘two-base enzymes’),
while, in a few cases (the ‘one-base’ enzymes), a single active-
site base mediates catalysis.18,20,96 Many racemases/epimerases
are dimers, with the active site located at the dimer interface
and active-site bases contributed by both subunits;18,20,95 binding
of substrate often triggers movement of the subunits from an
‘open’ to a ‘closed’ conformation, moving the active-site bases
into position and desolvating the active site.20,94,97,98 In some
enzymes (e.g. glutamate racemase21), this conformational change
triggers a change in the conformation of the deprotonating active-
site base as part of the pre-activation step which results in
protonation of the substrate carboxylate group. It has also been
suggested that conformational changes by ‘capping domains’,
which result in the closed form of the racemase, activate the
enzyme for catalysis, are important, e.g. in mandelate racemase.94
In other cases, little or no conformational changes are observed in
the protein upon binding of substrate and the enzyme active site
is substantially desolvated in the unbound state.20,95
Active-site bases
PLP-dependent enzymes use several different active-site bases.
In alanine racemase, these are generally thought to be Tyr-265
and Lys-39 (Fig. 1).5,69,70,99 Chemical models suggest that the
pKa of these active-site bases are increased to B21 (Lys) and
B28 (Tyr), respectively, in the hydrophobic active site.100 This
is considerably higher than the experimentally-determined
Ca–H pKa value of 11
101 and 9.94.87 Hence, deprotonation of
the substrate is expected to be facile. In serine racemase, the
corresponding active-site bases are Lys-57 and Ser-8269 and the
experimentally determined external aldimine Ca–H pKa value is
9.26.87 Chemical models suggest that their active site base pKa
values will be B21 and 33–39,100 the latter being extremely
high. These pKa values will be modified by hydrogen-bonding
networks within the active site, to allow deprotonation of
the active-site residues and reprotonation of the carbanionic
intermediate (vide supra, Schemes 1 and 2, 3).
The N-succinylamino acid racemases and related enolase
enzymes, e.g. O-succinylbenzoate synthase,102,103 utilise a pair
of lysine residues as catalytic bases49,104 (Fig. 2). Chemical
models100 suggest that the pKa for these lysine residues within
the active site will be B21. The Ca–H pKa for these substrates
Fig. 1 Active site residues of B. stearothermophilus alanine racemase
showing the external aldimine (alanine conjugated to PLP) and active site
bases Lys-39 and Tyr-265 (PDB: 1L6F).99
Fig. 2 Active site residues of an N-acetyl-amino-acid racemase, showing
binding of N-acetyl-methionine substrate (PDB: 4A6G).104
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ligated to active-site metals appears not to have been calculated,
though studies on other metal-dependent enzymes (mandelate
racemase)101 suggests that this will be B15.
Several different active-site bases are used by the cofactor-
independent racemases and epimerases. In most amino-acid
racemases/epimerases, both active-site bases are Cys, which act
as a thiolate base/thiol acid pair, catalysing deprotonation
and deprotonation,18,20 e.g. Cys-74 and Cys-185 in B. subtilis
glutamate racemase105 (Fig. 3). Cys is favoured as an active-site
base in amino-acid racemases and epimerases because it is
more easily desolvated and has a lower pKa than Ser or Thr.
106
Chemical models suggest that desolvation raises the pKa of the
Cys residue thiol to thiolate conversion to B28,100 matching
the expected pKa of the Ca–H of B29.
20,86 This allows deproto-
nation of the Ca–H by the Cys thiolate. In contrast, the pKa
values of the active-site Cys residues acting as an acid appear to
be B6–7 to enable protonation from the opposite side. This
change in pKa appears to be mediated by a dipole on the
a-helices bearing the Cys thiol (at least in diaminopimelate
epimerase20,107). Exceptions to this rule include aspartate/
glutamate racemase from a pathogenic E. coli strain (Ecl-DER),
in which one of the catalytic Cys is replaced by Thr. This enzyme
catalyses irreversible conversion of S-Asp to R-Asp, which arises
partly because of differences in the pKa values of the Cys and Thr
side-chains and partly because of differences in the distance
between the Ca–H and the catalytic bases on either side of the
substrate.20,108,109 Similarly, MMP0739 aspartate/glutamate race-
mase from Methanococcus maripaludis possesses active-site Cys
and Thr residues and is predicted to catalyse unidirectional
enantiomerisation42 (the opposite catalytic base is replaced
compared to the aspartate/glutamate racemase exception noted
above20). The H. sapiens trans-3-hydroxy-S-proline epimerase110
also possesses an equivalent Cys-to-Thr substitution to that in
MMP0739.42 However, biochemical analysis shows that this Cys-
to-Thr substitution converts the latter enzyme from an epimer-
ase into a dehydratase,110 i.e. the enzyme catalyses elimination
rather than racemisation/epimerisation (vide infra).
Other racemases and epimerases use a variety of active-site
bases, including Cys/Cys (allantoin racemase71), His/Lys (mande-
late racemase71), Glu/Glu or Asp/Asp (several different epimerases
acting on sugar substrates71), Glu/Glu (methylmalonyl-CoA
epimerase90), Tyr/Glu (heparin sulfate D-glucuronosyl C-5
epimerase71), Glu/His or Tyr/His (various sugar mutarotatases71),
Lys/Lys (various N-succinylamino-acid racemases and enolase
family racemases18,49), an Asp/His pair and Tyr (dTDP-
diphosphate-4-keto-6-deoxyglucose 3,5-epimerase a.k.a. RmlC),111
and a Glu/His pair and Asp (AMACR and MCR71,81,95,112).
N-Acetylmannosamine-6-phosphate 2-epimerase appears to be
an exception to this rule, as only one active site base/acid (Lys)
has been identified.18,96
The active sites of these other racemases and epimerases
also exclude bulk solvent.95 Chemical models100 again suggest
that the pKa of these active-site bases are correspondingly
increased to B29 (His), B21 (Lys), B22 (Asp and Glu), and
B28 (Tyr), again matching approximately the expected pKa
values of the substrate Ca–H. Each of these bases participates
in a hydrogen-bonding network with other active site residues
and, in some cases, active-site ordered waters.
An often-overlooked consideration in the catalytic mecha-
nism is the hydrogen bonding between the electron-deficient
Ca–H (which are activated by adjacent carbonyl groups) and
active-site bases. This is of relevance for all proteins, since all
protein amino-acid residues are capable of forming such
bonds.113 These hydrogen bonds tend to be moderately
weak (8 to 10.6 kJ mol1 when bonding to water compared to
18.9 kJ mol1 for an ‘typical’ intra-molecular bond114). In
addition, amino-acids and other racemase/epimerase substrates
will also be able to form such bonds. The case of the Ca–H/His/
Glu hydrogen bond in AMACR/MCR is particularly interesting in
this regard (Fig. 4), as the hydrogen bond resembles that in the
catalytic triad of chymotrypsin and related hydrolytic enzymes
which has been studied in detail.115
Concerted versus stepwise reactions
The PLP-dependent enzymes have been extensively studied and
a series of mechanistic and computational studies show the
Fig. 3 Active site of glutamate racemase from B. subtilis showing bound
R-glutamate substrate and active site bases, the cysteine residues, Cys-74
and Cys-185 (PDB: 1ZUW).105 Hydrogen bonds are shown as green dashed
lines.
Fig. 4 Active-site arrangement of a-methylacyl-CoA racemase (MCR)
from M. tuberculosis showing binding of binding of 2-methyltetra-
decanoyl-CoA substrate (PDB: 2GCI).95 Active site bases include Asp-156
and the His-126/Glu-241 pair, with Glu-241 contributed by the second
monomer subunit. The His-126/Glu-241 pair removes the a-proton of the
S-2-methylacyl-CoA substrate whilst Asp-156 protonates the enolate
intermediate.6,7,81,95 The roles of these residues are reversed for the
R-2-methylacyl-CoA substrate. Met-188 stabilises formation of the
enolate intermediate.
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presence of a carbanionic intermediate (vide supra, Schemes 1
and 2, 3),5,50,69,70,101 indicating a step-wise reaction. Kinetic
isotope effect studies on alanine racemase are also consistent
with a carbanionic intermediate.87 Alanine racemase catalyses
Ca–H exchange but the stereochemical course of this reaction
was not determined,116 although non-stereoselective incorpora-
tion of label into substrate is expected because of the stability of
the carbanionic intermediate.
Studies investigating isotopic incorporation from solvent
into substrates have been particularly informative about the
concertedness of mechanism in other enzymes. For the major-
ity of enolase family and cofactor-independent racemases and
epimerases, isotopic incorporation is observed into the product
but very little incorporation is observed into the substrate,
e.g. glutamate racemase,78 proline racemase,77 mandelate
racemase,74 2-methylmalonyl-CoA epimerase73 and a racemase
mediating post-translational modification of peptides.117 This
is consistent with a concerted reaction. Monitoring the pro-
gress of the reaction by these enzymes in isotopically labelled
solvent using circular dichroism typically results in an over-
shoot of the equilibrium position, e.g. as has been observed for
mandelate racemase.74 This results from isotopic incorporation
into product only with a significant kinetic deuterium isotope
effect affecting the reverse reaction. These results further support
a mechanism in which two-base enzymes catalyse a microscopic
enantiomerisation reaction, with asynchronously concerted
deprotonation and reprotonation.76 Such a mechanism mini-
mises the formation of a highly unstable doubly deprotonated
intermediate and hence partly overcomes the effect of destabi-
lising groups adjacent to the Ca–H (i.e. the carboxylate).
In contrast to the above is the observation that incubation of
substrates with AMACR in 2H2O results in a near 1 : 1 incor-
poration of deuterium into substrate and product. This has
been interpreted as formation of a discrete deprotonated
intermediate followed by deuteration from either side.79,80
Analysis of the crystal structure of the M. tuberculosis homo-
logue, MCR, shows catalytic residues on both sides of the
substrate (the His-126/Glu-241 pair and Asp-156; Fig. 4) and
are consistent with the formation of an enolate
intermediate.81,95,112 Thus, AMACR and MCR fundamentally
differ in their mechanisms from most other cofactor-
independent racemases and epimerases, in that they catalyse
microscopic racemisation rather than epimerisation.8,79,80
Incorporation of deuterium from solvent is also catalysed by
hydantoin racemase via an enolate intermediate118 and is
expected to be non-stereoselective but this has not yet been
verified.
The above results can be rationalised based on the pKa
values for the deprotonation of the substrate. The pKa of
Ca–H for a thioester is 21,
86,88 while the pKa values for Ca–H
for amino-acid zwitterions is 29,20,86 for simple carboxylates is
33 and for simple amides 28.4.86 Therefore, concerted reactions
occur with substrates containing relatively unactivated Ca–H
(high pKa values), with consequent asymmetrical isotopic incor-
poration. This explains the behaviour of peptide epimerases,117
which are observed to undergo concerted reactions. These peptide
substrates have pKa values of B26–31 for Ca–H, although these
values are dependent on both N- and C-substituents and the
protonation status of amine groups.86 This model also allows
prediction of enzymatic behaviour for uncharacterised racemases/
epimerases, e.g. hydantoin racemase,118 based on pKa values for
Ca–H. The proposed model also casts doubt on the use of isotopic
labelling studies to differentiate between ‘two-base’ and ‘one-base’
enzymes (reviewed in ref. 92). It has previously been proposed that
near-symmetrical isotopic incorporation into substrate and pro-
duct is indicative of ‘internal return’, i.e. a ‘one-base’ mechanism.
The results on AMACR79,80 (reviewed in ref. 6 and 7) show that this
behaviour is also observed with ‘two-base’ enzymes with activated
Ca–H, as it is known that AMACR/MCR possesses appropriate
active-site bases on both sides of the substrate.
Elimination reactions
Several racemases/epimerases catalyse elimination reactions,
in addition to racemisation/epimerisation. With the exception
of the ‘mutant’ H. sapiens trans-3-hydroxy-S-proline epimerase
containing a Cys-to-Thr substitution noted above110 giving rise
to dehydratase activity, and the Labrenzia aggregata cis-3-
hydroxy-S-proline racemase/dehydratase (IAM 12614)119 (vide
infra), all of the known elimination reactions take place with
unnatural substrates. The vast majority of these unnatural
substrates are halogen derivatives,20,47,63,82,120–126 with only a
few exceptions.63,119,124,127,128 The deprotonation step in the
elimination reaction is highly similar to that described for
racemisation/epimerisation (vide supra).
Several PLP-dependent racemases catalyse elimination
reactions.129–133 The classic example is alanine racemase
(Scheme 3) which b-eliminates halogens from 3-fluoroalanine
12 and 3-chloroalanine 13.132 O-Carbamoyl-R-serine 14R and
O-acetyl-R-serine 15R act as irreversible inhibitors whilst
O-carbamoyl-S-serine 14S and O-acetyl-S-serine 15S are reversi-
ble competitive inhibitors.132 3-Fluoroalanine 12 is a potent
inactivator of alanine racemase. 3-Chloroalanine 13 and
O-carbamoyl-S-serine 14 and O-acetyl-S-serine 15 also act as
substrates. These substrates result in the formation of
2-aminoacrylate 16, which tautomerises to pyruvate 17 with a
Scheme 3 (A) Structures of eliminating inhibitors and substrates of E. coli
alanine racemase; (B) conversion of O-acetyl-S-serine 15S to pyruvate 17
by alanine racemase.132
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partition coefficient of between 790 and 920 to 1 (catalytic
conversion/inactivation).
There have also been several studies on the elimination
reaction catalysed by H. sapiens serine racemase.129–131,133 The
wild-type enzyme has a ca. 4-fold preference for b-elimination
over racemisation of S-serine.129,131 Other substrates can also
undergo b-elimination, including S-serine-O-sulfate and
S-threo-hydroxyaspartate.131 The enzyme is allosterically activated
by divalent metal ions (with Mn2+ being the strongest) and
ATP,129,133 and activity is potentiated by halide anions.130 The
elimination reaction catalysed by serine racemase is thought to
control levels of R-serine in neurons133 and, hence, modulate the
activity of NMDA receptors;129,131,133 over-activation of the NMDA
receptor has been shown to result in neuronal cell death.133 This
is, however, at the expense of producing highly electrophilic
2-aminoacrylate 16.129,131,133
Enolase family enzymes, such as P. putida mandelate
racemase126 and L. aggregata cis-3-hydroxy-S-proline racemase/
dehydratase (IAM 12614),119 are also able to catalyse elimina-
tion reactions. Mandelate racemase was able to catalyse elim-
ination of chlorine from 3-chlorolactate 18 to give pyruvate 19
(Scheme 4A).126 The mechanistic details of the reaction was not
determined but it is assumed to occur by E2 anti-elimination to
give the enol 20 followed by tautomerisation.126 However, the
possibility of a E1cb-type mechanism via an enediolate type
intermediate cannot be discounted. The elimination of chlorine
from 3-chlorolactate 18 by mandelate racemase is reminiscent of
the elimination of HCl from 3-chloroalanine 13 by glutamate
racemase, which also gives pyruvate 17 as a product (vide infra,
Scheme 12).134 This result contrasts with the earlier observation
on P. putida mandelate racemase with 3,3,3-trifluorolactate 21,
which undergoes racemisation. b-Elimination to give 22 is not
observed (Scheme 4B).91
L. aggregata cis-3-hydroxy-S-proline racemase/dehydratase
(IAM 12614)119 catalyses both racemisation and b-elimination
reactions with its substrate 23, in a 3 to 2 ratio (Scheme 5). The
b-elimination reaction is proposed to go via an enediolate
intermediate 24, although it may be a more concerted E2-like
reaction. The cis substrate allows for anti-elimination of
the hydroxy group to give the enamine product 26, which
subsequently tautomerises to D-pyrroline-2-carboxylate 27
(Scheme 5). Alternatively, epimerisation to give 25 can occur.
It is notable that 27 is a known inhibitor of T. cruzi proline
racemase.135
The cofactor-independent enzymes diaminopimelate
epimerase124 and glutamate racemase128 are able to eliminate
N-hydroxy substrates. In the case of glutamate racemase,
deprotonation of substrate 28 results in elimination of hydro-
xide or water with formation of imine 29, which is hydrolysed to
2-oxoglutarate 30 (Scheme 6).
With aliphatic substrates containing b-fluorine or b-chlorine,
the presence of the halogen increases the acidity of the
Ca–H,
120,136 and, hence, these elimination substrates tend to
be converted with somewhat higher efficiency than their
Scheme 4 Reaction of halogen substrates with P. putida mandelate
racemase.91,126 (A) Elimination of chlorine from 3-chlorolactate 18;126
(B) expected elimination of 3,3,3-trifluorolactate 21 to give 22.91
Scheme 5 The racemisation and elimination reactions catalysed by
cis-3-hydroxy-S-proline racemase/dehydratase.119
Scheme 6 Elimination of N-hydroxy-R-glutamate 28 by an E2 mecha-
nism followed by hydrolysis of imine 29 to form 2-oxoglutarate 30.128
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racemisation/epimerisation equivalents.120 With diaminopimelate
epimerase,121 only stereoisomers allowing an antiperiplanar
conformation between the Ca–H and the fluorine underwent
elimination, with substrates not allowing an antiperiplanar
conformation undergoing epimerisation instead. Similarly,
mutant glutamate racemases (in which the active-site Cys bases
were mutated to Ser) eliminated either 2R,3R- or 2S,3S-3-
chloroglutamate stereoisomers 31R and 31S with anti-
elimination (Scheme 7), depending on which active site Cys
residue was still present.82 The resulting enamine 32 tauto-
merises to imine 29, which is hydrolysed to 2-oxoglutarate 30.
These results are consistent with a substantially concerted (E2)
mechanism.137
The above results contrast with those observed with AMACR,
in which epimeric substrates 33 and 34 were eliminated to the
same product 35,120 consistent with an E1cb mechanism
through the enolate intermediate 36 (Scheme 8).137 These
results are inconsistent with an E2-elimination because the
substrate requires a conformation in which the a-H and the
fluorine are anti-; epimer 33 can adopt such a conformation but
epimer 34 cannot. Interestingly, compounds closely related to
33 and 34 were synthesised136 and tested as inhibitors of native
rat AMACR and no elimination of fluoride was observed.136
These inhibitors136 had the same configuration as 34 (and its
epimer with opposite C2 and C3 configurations) but, in view of
the subsequent report,120 this is a surprising observation.
However, this is not the only example where an expected
elimination reaction did not take place. Nagar et al. investi-
gated trifluorolactate (2-hydroxy-3,3,3-trifluoropropanoate) 9R
and 9S as substrates for mandelate racemase (vide supra,
Scheme 4).91 Kinetic analysis showed that Km values for tri-
fluorolactate 9 were unexpectedly similar to the natural sub-
strate, mandelate (1.2–1.74 mM and 1.0–1.2 mM, respectively)
and lower than the predicted Km value of B10 mM. In contrast,
kcat values were reduced by B318-fold, with kcat/Km reduced
by B430-fold. 19F NMR analysis showed that no fluoride was
eliminated during the reaction and, hence, 10 was not formed.91
The lack of a b-elimination reaction is unexpected, because the
trifluorolactate 9 is able to take up the required anti-conformation
for an E2 reaction when in a staggered conformation. Clearly, the
mandelate racemase-catalysed racemisation of trifluorolactate is
faster than the elimination reaction. The reasons for this are
unclear but it could be related to the presence of multiple fluorine
atoms within the substrate.138 If loss of fluoride is asynchronous
with abstraction of the Ca–H, this will result in generation of a
positive charge on the b-carbon. The presence of two additional
fluorine atoms will destabilise formation of this transition state.
However, it is notable that E. coli dipeptide epimerase (YcjG)
eliminates fluoride from S-alanyl-R,S-difluoroalanine in prefer-
ence to epimerisation,125 suggesting that other factors are also
at play such as the extent of d+ charge stabilisation in the
transition state.
Methods for determining racemase
and epimerase activity
Racemases and epimerases are simple enzymes, in the sense
that they only have one substrate and product (a uni-uni
reaction), which is a characteristic they share with other
isomerases. A consequence of racemases and epimerases
accepting both stereochemical configurations of their sub-
strates is that their reaction will, in most cases, be readily
reversible and kcat/Km values are likely to be similar for the
reactions in both directions (which is required by the Haldane
relationship79,80,139 for an equilibrium constant of B1). Hence
the rate for the reverse reaction when determining initial rates
is likely to be significant and this must be corrected for in any
kinetic study, such as the determination of inhibitor potency.
Several different assays exist for measuring racemase/
epimerase activity (Table 1). One approach is to measure rates
Scheme 7 b-Elimination of 2S,3S-3-chloroglutamate 31S by Lactobacil-
lus glutamate racemase to give enamine 32. Tautomerisation to imine 29
followed by hydrolysis gives the resulting 2-oxoglutarate 30.82
Scheme 8 Elimination of fluoride from substrates by a-methylacyl-CoA
racemase.120 For substrates 33 and 34, n = 6. For inhibitors (34 and its
epimer with opposite C2 and C3 configuration) tested on native rat
enzyme reported not to eliminate,136 n = 12. Enzyme catalytic residue
numbers are those for human AMACR.6,7
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at very early time points where the reverse reaction will have
less impact. Typically, the enzyme reaction is followed using
techniques such as optical rotation46,140–145 or circular
dichroism,23,91,107,146–150 allowing a time-course to be deter-
mined. These assays are ideal, in that they allow much more
accurate determination of initial rates,151 although correction
for the reverse reaction should still be performed. Indeed,
circular dichroism is by far the most common method of
detecting enzymatic activity (Table 1), although it is noted that
these are kinetic studies designed to measure Km, kcat and
kcat/Km (vide infra).
A second alternative when analysing substrates undergoing
racemisation or epimerisation is to use HPLC of a diastereo-
isomeric substrate/product mixture at a fixed time point,37,136
although the differences in energies between diastereoisomers
means that these substrates may behave differently from natural
enantiomeric substrates. Alternatively, a product containing one
chiral centre can be derivatised using a chiral reagent and
analysed by HPLC, GC or NMR.8,79,80 The latter approach is
time-consuming, as several time-points for each reaction should
be analysed and can be technically challenging, especially when
working with the low amounts of product typically obtained from
enzymatic reactions. Chiral HPLC is an option for separating
enantiomeric substrates, although there appear to be no examples
of this having been used.
A second approach is to measure exchange of the a-proton
with isotopically labelled substrates82,95,152–154 or solvent,8,73,78–80,107
measuring reaction extent by scintillation counting, mass
spectrometry or NMR. Such approaches will introduce signifi-
cant kinetic isotope effects155–158 and deprotonation and repro-
tonation rates will be markedly different from each other
although the extent of this will depend on levels of conversion
of substrate and whether the transition states are early or
late.107 Consequently, careful design of experiments is needed,
especially where precise rate measurements are required.
These approaches are often used in mechanistic studies where
isotopic distribution in substrate and product is measured
(vide supra).
A third approach is to make the enzymatic reaction
irreversible. This can be achieved using an irreversible coupled
enzyme to remove the reaction product.107,159,160 There are a
number of examples of the use of coupling enzymes in kinetic
studies determining Km and kcat values (Table 1). The most
common coupling enzymes used are D-amino acid oxidase and
NAD-dependent oxidoreductases. Coupled enzyme assays are
the second most common method of assessing enzymatic
activity. Similarly, an unnatural substrate which undergoes an
irreversible elimination reaction82,83,120,127,161 can also be used.
Typical examples of eliminated groups include water (from
amino-acid hydroxamate derivatives83,162), bromide,122,123
chloride47,82,124 and fluoride120,121,124,125,161 as described above.
The products from these elimination reactions often need to be
assayed using coupling enzymes83,121 or low-throughput spec-
troscopic techniques such as NMR.120,121,161 Attempts to use
fluoride sensors to measure enzymatic activity with substrates
eliminating fluorine has met with limited success.161 A notable
example of this approach is the elimination reaction of an
unnatural acyl-CoA substrate 37 by AMACR to give 2,4-
dinitrophenoxide 38 and acyl-CoA 39 (Scheme 9);127 this assay
was used in a high-throughput screening campaign of 20 387
compounds which identified novel pyrazoloquinolines and
pyrazolopyrimidines as inhibitors163 and also in the first exten-
sive inhibitor structure–activity relationship studies on any
racemase/epimerase (vide infra).164,165
Catalytic efficiency of racemases and
epimerases
Kinetic parameters for racemases/epimerases can vary quite
widely (Table 1). Km values for amino-acid racemases tend to be
in the low mM range, although there are several examples
where much higher Km values have been measured. Typical
examples include Fusobacterium nucleatum and B. subtilis
glutamate racemase, which have Km values of 1.04 and 1.07 mM
and 14 and 1.24 mM, respectively.166 In contrast, O-ureidoserine
racemase which has reported Km values
46 of 12 and 32 mM for
S- and R-O-ureidoserine, respectively. In contrast, the Km for
S,S-diaminopimelate (2,6-diaminoheptanedioic acid) for
M. tuberculosis diaminopimelate epimerase is only 166 mM,167
significantly lower than the Km values for other amino-acid
racemases/epimerases. The relatively high Km values for most
amino-acid racemases/epimerases are undoubtedly a conse-
quence of these enzymes converting small and relatively
unfunctionalised substrates. The same trend is observed for
mandelate racemase, which has Km values of 1.0 and 1.2 mM
for S- and R-mandelate (2-hydroxyphenylacetate), respectively.91
Racemases/epimerases with larger substrates tend to have
lower Km values, as there is more opportunity for binding
interactions. For example, human AMACR has a Km value of
B86 mM for pristanoyl-CoA,152 while Km values for S- and
R-ibuprofenoyl-CoA are 86 and 48 mM for the M. tuberculosis
Scheme 9 Colorimetric assay for a-methylacyl-CoA racemase (AMACR)
based on elimination of 2,4-dinitrophenolate 38 from the acyl-CoA sub-
strate 37.127 (A) Reaction catalysed by AMACR; (B) assay samples showing
reaction with heat-inactivated enzyme (red circle) and active enzyme
(green circle) showing absorbance at 354 nm;127 (C) measurement of
dose–response curve for Rose Bengal (a known inhibitor of
AMACR127,152) using the colorimetric assay. Schemes 9B and C have been
reproduced from Yevglevskis et al., 2017127 with permission from the Royal
Society of Chemistry.
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homologue.146 These lower Km values are generally accompa-
nied by lower kcat values (Table 1).
Catalytic efficiency is quantified using kcat/Km values
(Table 1). Again, these can vary quite widely but many race-
mases/epimerases have relatively modest efficiencies. For
example, O-ureidoserine racemase is quite efficient, with
reported kcat/Km values
46 of 39 583 and 45 312 M1 s1.
Similarly, kcat/Km is reported to be 16 730 and 15 294 M
1 s1
for F. nucleatum glutamate racemase for S- and R-Glu, while the
corresponding values are 3000 and 3806 M1 s1 for the B.
subtilis enzyme.166 In contrast, M. tuberculosis diaminopimelate
epimerase167 has a very modest kcat/Km of 883 M
1 s1. On the
other hand, RacX168 has extremely low kcat/Km values of 2.86
and 3.23 M1 s1 for S- and R-Lys, while YgeA168 has kcat/Km
values of 45.8 and 45.8 M1 s1 for S- and R-His.
kcat/Km values for other racemases and epimerases tend to
be higher and this is often related to the lower Km values
observed for these larger substrates. For example, mandelate
racemase (6.2 and 6.5  105 M1 s1 for S- and R-mandelate91)
and the M. tuberculosis homologue of AMACR (5.23  106 and
6.0  106 M1 s1 for S- and R-ibuprofenoyl-CoA,146 respectively).
Finally, N-succinylamino acid racemases and N-acetylamino acid
racemases exhibit highly variable kcat/Km values (Table 1).
It is noteworthy that even the most efficient racemases/
epimerases have kcat/Km values well below the theoretical
diffusion-controlled maximum of B1  109 M1 s1.169
As proton-transfer reactions are extremely fast (between 5 
109 and 1  1011 M1 s1),86 rates may be limited by binding of
substrate, release of product or conformational changes in the
protein. A survey of kcat/Km values for various enzymes
169 shows
that, for most enzymes, they are around 105 to 109 M1 s1,
with the most efficient enzyme (superoxide dismutase) having a
kcat/Km of 7  109 M1 s1. Moreover, kcat/Km values for most
enzyme-catalysed reactions appear to be diffusion-limited.169
There have been few detailed kinetic studies on racemases/
epimerases but studies on mandelate racemase using mande-
late as a substrate show that both kcat and kcat/Km are affected
by increasing the viscosity of the solvent.170,171 This indicates
that both binding of substrate and release of product are partly
rate-limiting, although the effects on kcat are more extensive
than those on kcat/Km indicating that that release of product is
more sensitive to solvent viscosity than binding of substrate.172
In contrast, poorer substrates of mandelate racemase91 or less
active mutants of the enzyme173 tend to be unaffected by
increasing solvent viscosity, suggesting that rates are limited
by the chemical reaction or other processes, e.g. conformational
changes in the protein. Although the kcat/Km values for mandelate
racemisation is relatively modest (6.2 and 6.5  105 M1 s1)91
compared to these other enzymes, it should be noted that
racemisation of mandelate is a ‘difficult’ reaction as judged
by the estimated half-life for the spontaneous uncatalysed
reaction of 9.8  104 year.169 Thus, mandelate racemase is
providing a considerable enhancement (an effective molarity
of B4.87  106 M). It is unclear whether racemases/
epimerases with lower kcat/Km values are limited by diffusion,
chemical reactivity or other processes, or whether these low
efficiencies result from a low amount of active enzyme within
the enzyme preparation.
Drug design strategies for inhibiting
racemases and epimerases
As noted above, many racemases and epimerases are drug targets
for various diseases. The following is a survey of different
strategies for the development of inhibitors.
Substrate/product analogues
Exploiting the differences in side-chain conformation of different
racemase/epimerase substrate stereochemical isomers can be a
particularly fruitful strategy for the development of inhibitors.
A significant advantage of these inhibitors is that they are achiral
when identical sidechains are used. The substrate/product ana-
logue approach works particularly well for racemases/epimerases
possessing discrete side-chain-binding pockets for the different
stereoisomers, e.g. mandelate racemase139 and M. tuberculosis
a-methylacyl-CoA racemase (MCR).149 It can also work for
enzymes with more subtle changes in side-chain conformation,
e.g. aspartate racemase174 and glutamate racemase,175 although
the potency of inhibition tends to be more modest. In many
respects, substrate/product analogues are the equivalent of bisub-
strate inhibitors of other enzymes,176 which often give rise to
potent inhibition.
Several substrate/product analogues have been reported as
inhibitors of amino-acid racemases (Fig. 5). For example, citrate
40 was shown by X-ray crystallography to bind as a substrate/
product analogue to aspartate racemase.174 Citrate 40 behaves
as a competitive inhibitor, although the potency was very low
(Ki = 7.4 mM vs. Km = 0.74 mM for L-aspartate). Pal et al.
designed cyclic inhibitors of glutamate racemase, in which
the ring mimicked the side-chain positions for the different
stereoisomers of glutamate, including compound 41.175
This proved to be a partial non-competitive inhibitor, although
potency was modest (Ki = 3.1 mM vs. Km = 1.41 mM for
Fig. 5 Structures of representative substrate–product analogues which
are inhibitors of aspartate racemase (40),174 glutamate racemase (41),175
serine racemase (42),188 proline racemase (43),188 mandelate racemase
(44)139 and M. tuberculosis a-methylacyl-CoA racemase (MCR) (45).149
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substrate S-glutamate).175 In contrast, substrate/product analo-
gues were poor inhibitors of serine racemase (e.g. 42, mixed
competitive inhibition; Ki = 167 mM and Ki’ = 661 mM vs.
Km = 19 mM)
188 and proline racemase (e.g. 43, non-competitive
inhibition; Ki = 111 mM vs. Km = 5.7 mM).
188 Proline racemase
is known to have an extremely confined active site in the
‘closed form’ of the enzyme,26,27 which binds substrates and
inhibitors.
There have only been two substrate/product analogue
studies on non-amino-acid racemases. Mandelate racemase
substrate/product analogues139 bind with similar affinity to the
substrate [e.g. benzilate (2,2-diphenyl-2-hydroxyacetate) 44, Ki =
0.67 mM vs. Km = 0.70 and 0.54 mM for R- and S-mandelate,
respectively139]. Similarly, a substrate–product analogue of
ibuprofenoyl-CoA (Fig. 5, 45a) was a competitive inhibitor of
the M. tuberculosis homologue of AMACR (MCR) and showed
about a 6-fold increase in binding affinity (Ki = 16.9 mM vs. Km = 106
mM) compared to ibuprofenoyl-CoA, undoubtedly due to the side-
chain of the inhibitor binding to both the R- and S- subsites.149
Enhancing acidity of the a-proton and alternative substrates
A number of racemases/epimerases have alternative substrates
which undergo changes in stereochemical configura-
tion8,91,127,164,189 or elimination.63,82,120–124,128,161,164 Efficiency
of inhibition is dependent on concentrations of inhibitor and
their catalytic efficiency as substrates (kcat/Km). Alternative
substrates are usually competitive inhibitors (for example
see127), which means that inhibition can be overcome by high
concentrations of the substrate whose conversion is being
inhibited.
Efficient inhibition can be achieved by increasing the acidity
of the Ca–H, e.g. by use of trifluoromethyl group (Fig. 6, 47 and
48).136,190 The trifluoromethyl group lowers the energy of
the enolate intermediate81 in the AMACR reaction;136 inter-
mediates generally bind tightly to enzymes and more closely
resemble the transition states of the reaction.94 The presence of
a sulfur atom immediately adjacent to the substrate Ca–H is
also an effective strategy for increasing acidity (vide infra,
Fig. 29).165
Preventing the removal of the a-proton
These types of inhibitors fall into two types: those in which the
Ca–H has been replaced by an alternative group and those with
neighbouring groups which decrease the acidity of the Ca–H.
A number of different groups have been used to replace the
Ca–H (in addition to the substrate/product analogues with
a second side-chain noted above), including fluorine atoms,
e.g. 49,191 and methylene groups, e.g. 50192 (Fig. 7).
Inhibitors can also have substituents adjacent to the Ca–H,
which raise the energy of the deprotonated intermediate, such
as hydroxy groups as exemplified by 519,164 and 52164 (Fig. 8).
Exchange of the Ca–H was shown not to occur by incorporation
studies in 2H2O and
1H NMR analyses when 51 and 52 were
tested as substrates for AMACR.9,164 In all cases, these
approaches tend to give rise to moderate inhibitors, as judged
by the ratio of IC50/Km or Ki/Km values.
Transition-state and intermediate analogues
Transition-state analogues are widely recognised as potent
drugs.135,193,194 This approach has been relatively under-used as
a strategy for inhibition of racemases and epimerases, although
the few examples show that highly potent inhibitors can be
obtained.
An early example is proline racemase, which is inhibited by
pyrrole-2-carboxylate 53 and D-pyrroline-2-carboxylate 27
(reviewed in ref. 135) (Fig. 9A). Relatively high concentrations
Fig. 6 Representative inhibitors with increased Ca–H acidity.
136,165,190
Fig. 7 Representative inhibitors in which the Ca–H is replaced.
191,192
Fig. 8 Representative inhibitors in which the acidity of Ca–H is decreased.
164,191
Fig. 9 (A) Structures of proline racemase transition-state analogues.135
Log P values were calculated using: https://www.molinspiration.com/
cgi-bin/properties. Log P, log10 (ratio of concentrations of drug in octan-
1-ol and water at equilibrium); (B) X-ray crystal structure of pyrrole-2-
carboxylate 53 bound within the active site of proline racemase from
T. cruzi,195 showing the catalytic bases Cys-130 and Cys-300. Hydrogen
bonds are shown as green dashed lines.
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of these compounds are required for inhibition in vitro of the
enzyme (about 10  that of substrate) and they should be
considered as inhibitors in which the Ca–H is replaced (vide
supra). X-ray crystallographic analysis showed that pyrrole-2-
carboxylate binds within the T. cruzi active site (Fig. 9B)
between the catalytic bases Cys-130 and Cys-300.195 However,
despite its relatively low potency, pyrrole-2-carboxylate 53
reduced invasion of T. cruzi in infected mammalian cell models
and also reduced differentiation of the parasite from the
amastigote form into trypomastigotes.28 A number of more
water-soluble analogues (e.g. 54 and 55) were tested for their
ability to inhibit the enzyme but these proved to have lower
potency.26 Compounds 53, 54 and 55 had similar lipophilicity
(calculated log P values of 2.41, 2.33 and 2.20, respectively)
and the loss of inhibitory activity is likely to be related to the
difficulties of accommodating the bulky halogen in the highly
restricted active site. The halogen atom in 54 and 55 is also
likely to force the carboxylate group out of plane, and this is
expected to have a significant impact on binding affinity.
A more recent example of the use of transition-state analo-
gues are the carbamate inhibitors of a-methylacyl-CoA race-
mase (Fig. 10),191 which mimic the transition state (or enolate
intermediate), giving rise to highly potent inhibition.127,164,191
Although the carbamate inhibitor 56 is by far the most potent
AMACR inhibitor reported to date, it has limited utility because
acyl-CoAs violate Lipinski guidelines and inhibitors are deliv-
ered to cells as the carboxylic acid pro-drug. Unfortunately, the
acid pro-drug in this case would be a carbamate 57 which may
readily decompose164 especially under acidic conditions or in
the presence of cellular nucleophiles.
There are several other examples of using analogues of the
deprotonated intermediate as inhibitors. For example, the
conversion of mandelate by mandelate racemase is proposed
to go through an aci-carboxylate intermediate (Fig. 11, 58).196
Several mandelate racemase inhibitors of this type have been
reported, including the phosphonate inhibitors196,197 such as
the highly potent inhibitor 59 (Ki = 4.7 mM vs. Km of 1.0 and
1.2 mM for R- and S-mandelate, respectively). The phosphonate
group in 59 possesses two negatively charged oxygen atoms,
and hence resembles the aci-carboxylate intermediate 58.
Similarly, cupferron 60 and N-hydroxyformanilide 61 also act
as analogues of the deprotonated intermediate 58 because they
have an extended planar system of sp2-hybridised atoms, whilst
benzohydroxamate 62 is a hydroxamate. Inhibitors 59–62 (Fig. 11)
strongly ligate to the metal in the active site of mandelate
racemase (Ki values of 2.7, 2.8 and 9.3 mM, respectively).
198
Allosteric inhibition
Allosteric inhibition arises from inhibitors binding somewhere
other than at the enzyme active site. The uncompetitive type
of inhibition observed through enzyme kinetics arises from
binding of the inhibitor to the enzyme-substrate complex with
(almost) no binding to unoccupied enzyme199 and, hence, must
arise from binding at an allosteric site.
Glutamate racemase is the only racemase/epimerase for
which confirmed allosteric inhibitors have been reported.
Lundqvist et al. identified an uncompetitive inhibitor 63 during
a high-throughput screening campaign on the H. pylori enzyme
(Fig. 12).200 The inhibitor-binding site is remote from the active
site.21,200 A second cryptic inhibitor-binding site was subse-
quently identified in the B. anthracis enzyme by virtual screen-
ing, which led to the identification of pyridine-2,6-dicarboxylate
(dipicolinate) 64 as an inhibitor (Fig. 12), with Ki = 1.9 mM.
25
Further studies on 37 showed that inhibitor binding resulted in
the active-site Cys185 adopting a conformation in which the SH
group points away from glutamate Ca–H.
21 It is also noted that
some uncompetitive inhibitors of a-methylacyl-CoA racemase
were recently identified (vide infra, Fig. 15),163 implying that
they bind to an allosteric site, although the exact binding site
has not been confirmed.
Covalent inhibition
Inhibitors which form a covalent bond to their targets are
enjoying a resurgence because of their potential for long-
lasting effects and strong affinity for the target, amongst other
benefits.201–207 Indeed, around 30% of all approved clinical
drugs acting on enzymes are covalent inhibitors.202,207 Covalent
inhibitors can cause either reversible or irreversible inhibition of
their target.204–208 There is a perception that covalent inhibitors
are non-selective and hence are less useful. However, studiesFig. 10 Structure of the enolate intermediate analogue as an inhibitor of
AMACR191 and the unstable carbamate pro-drug.
Fig. 11 Inhibitors of mandelate racemase (59–62)196–198 resembling the
aci-carboxylate deprotonated intermediate 58.196
Fig. 12 Structures of the allosteric inhibitors 63 (H. pylori glutamate
racemase)200 and pyridine-2,6-dicarboxylate 64 (B. anthracis glutamate
racemase).25 The ionisation state of 64 which is shown is that used in the
virtual screen.
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have shown that high selectivity for the target enzyme can be
achieved.203–210 Modification of the substituents around the
electrophile can also further enhance selectivity,210–212 especially
for electrophiles modifying cysteine residues212–215 (which are
the catalytic bases in many cofactor-independent amino-acid
racemases and epimerases5,18,20,22). Electrophilic properties can
be predicted using the ‘electrophilicity index’.209
Covalent inhibition of racemases and epimerases has been
previously investigated. Both diaminopimelate epimerase20,124
and a-methylacyl-CoA racemase127,152 have been shown to be
inhibited by non-specific protein-modification agents. In each
case, these are cysteine-reactive compounds such as iodoacet-
amide, ebselen (2-phenyl-1,2-benzoisoselenazol-3(2H)-one) and
ebselen oxide. It is also noted that mandelate racemase under-
goes covalent inhibition by 3-hydroxypyruvate because of for-
mation of an imine between the inhibitor and Lys-166, one of
the active-site bases.216 There have also been several attempts
to design irreversible inhibitors rationally, most notably the
aziridine inhibitors of diaminopimelate epimerase.20,124,217,218
A recent example of rational covalent inhibitor design is seen
with O-ureidoserine racemase (which interconverts S- and
R- O-ureidoserine 65), which is irreversibly inhibited by oxi-
ranes R- and S-66 to give covalent adducts (Scheme 10).46
An irreversible inhibitor of B. subtilis glutamate racemase
was also identified by virtual screening (vide infra),23,24 and was
proposed to bind close to the catalytic cysteine residues.22 The
inhibitor is proposed to modify irreversibly one of these thiols
by conjugate addition (a.k.a. Michael addition).202,205,206 The hit
compound 67a and several analogues 67b–67d (Scheme 11A) were
subsequently shown to be irreversible inhibitors.22 Compounds
67a and 67c proved to be non-saturating inhibitors. In contrast,
67b and 67d displayed saturating inhibition, consistent with
modification of active site residues. Further experiments showed
that inhibition was reversible, consistent with a reversible
conjugate addition via enolate 68a to give the product 69a
(Scheme 11B). Mass spectrometric analysis of wild-type and
C74A mutant glutamate racemase following incubation with
67a confirmed modification of Cys-74, one of the active-site
bases. Compound 67a was unreactive with 2-mercaptoethanol
under the assay conditions,22 showing that conjugate addition
to thiols only occurred in the presence of the high nucleophilic
Cys-74 in the enzyme active site. The rhodanine warhead
(Scheme 11A) is recognised as a common motif found in pan-
assay interference compounds (PAINs), which give rise to false
positive or intractable leads in high-throughput screening
campaigns.219 These rhodanine glutamate racemase inhibitors
showed activity against various bacterial strains, including
various methicillin-resistant S. aureus strains.22
In a second study, 3-chloroalanine 70 (b-chloroalanine; a
poor inhibitor of PLP-dependent alanine racemase134) was
shown to irreversibly inactivate glutamate racemase from
M. tuberculosis.134 Non-saturating kinetics where observed for
the S-isomer with a second-order rate constant of 2.7 M1 s1.
Mass spectrometric analysis of peptides showed that 3-chloro-
S-alanine (70S) reacted at Cys-185, while 3-chloro-R-alanine
(70R) reacted at Cys-74. In the glutamate racemase reaction,
R-glutamate is deprotonated by Cys-74 whilst S-glutamate is
deprotonated by Cys-185 during enantiomerisation, i.e. the
active-site Cys acting as an acid is derivatised by 3-chloro-
alanine 70.
The authors proposed134 that the adduct was a pyruvate
derivative, based on the observation that pyruvate 71 was
generated upon treatment of the enzyme with 3-chloro-
alanine 70 but their proposed mechanism is very unlikely.
Two more likely mechanisms can be envisaged (Scheme 12,
pathways A and B) based on the observed increase in mass of
B87 Da. In pathway A, removal of the Ca–H of 70S by Cys-74
results in elimination of HCl, yielding the aminoacrylate
Scheme 10 (A) Interconversion of O-ureidoserine substrate isomers 64S
and 64R by O-ureidoserine racemase. (B) Inactivation of O-ureidoserine
racemase by epoxide 65S to give covalent adduct 66. The roles of the Cys
residues are reversed for the enantiomeric epoxide 65R.46
Scheme 11 (A) Structures of irreversible inhibitors of B. subtilis glutamate
racemase.22 The rhodanine motif is highlighted in red; (B) inactivation of
glutamate racemase by 68a by 1,4-conjugate addition.
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complex 72. This is followed by conjugate addition of Cys-185 to
give 73. However, complex 72 is achiral and non-specific
derivatisation of the active site Cys residues might be expected
if 72 resulted in alkylation. Pathway B, via the aziridine inter-
mediate 74, preserves the chirality of reaction and gives rise to
the same adduct 73. However, the active site Cys residues are
relatively distant from the a-amino group, making pathway B
less likely. Digestion of the derivatised enzyme and mass
spectrometric analysis shows the presence of nitrogen within
the enzyme-inhibitor adduct, discounting the possibility that
the adduct is a pyruvate derivative (Scheme 12, pathway C). The
observed pyruvate 17 generated in the reaction arises from
tautomerisation of aminoacrylate 72 to the imine followed
by hydrolysis, i.e. 70 behaves as a substrate as well as an
inhibitor.220
Similarly, two covalent inhibitors (77 and 78) of T. cruzi
proline racemase were identified by virtual screening.26 The
inhibitors were proposed to modify the active-site cysteine
residues26 by conjugate addition202,205,206 and this was subse-
quently confirmed by X-ray crystallography.27 The active com-
pounds (Scheme 13A) each have a double bond in conjugation
with a carboxylate and a ketone26,27 and X-ray crystallography
showed that conjugate addition occurred towards the ketone.27
This is unsurprising as ketone carbons are more d+ than
carboxylic acids/carboxylates and hence conjugate addition
is expected to occur towards the ketone. The most active
compound of those subsequently investigated (NG-P27, 79)27
was active against T. cruzi in infected mammalian cells. It is
also notable that one of the original compounds26 (5-bromo-4-
oxopent-2-enoate 78) is divalent and reacts with both active-site
cysteine residues, cross-linking the enzyme to give adduct 80
(Scheme 13B).27
Virtual screening and structure-based fragment screening
Virtual screening of drug targets with a compound library is a
well-established method in drug discovery.221–225 These
approaches can utilise artificial intelligence to optimise the
process223 or negative design222 to remove compounds which
are poor prospects.
There are only a few examples of virtual screening being
used for identification of inhibitors of racemases/epimerases
and all have been for amino-acid racemases. For example,
Skariyachan et al. conducted a screen of a virtual natural
products library against diaminopimelate epimerase, amongst
several other targets, identifying limonin 81 as a hit (Fig. 13).226
Limonin 81 and several other hits showed dose-dependent
activity against a clinical strain of multi-drug resistant
Acinetobacter baumannii.
Studies on B. subtilis glutamate racemase used ab initio
quantum mechanics/molecular mechanics to probe transi-
tion states in the reaction.23 A strong correlation between
computational and experimentally determined binding of
known inhibitors was observed. The same study23 used a
enzymatic transition state conformation in a virtual screen of
over one million compounds followed by experimental testing.
Although no tight-binding inhibitors were identified, several
common motifs for competitive inhibitors were identified.
A subsequent virtual screening study on the same enzyme24
identified several competitive inhibitors such as 64 and 82,
with the two most potent inhibitors, 83 and 84, having Ki values
of 59 and 42 mM (Fig. 14).
Virtual screening has also been used against proline race-
mase from T. cruzi, the causative agent of Chagas disease (vide
supra).26 Proline racemase without a ligand exists in an ‘open’
conformation. Upon binding of an inhibitor, a ‘closed’ con-
formation is adopted, such that a very restricted active site is
produced, which prevents design of inhibitors using standard
Scheme 13 (A) Structures of highly active covalent inhibitors of proline
racemase;26,27 (B) Reaction of 78 with catalytic cysteine residues in proline
racemase by conjugate addition and SN2 reaction to give a cross-linked
adduct 80.27 Fig. 13 Structure of limonin 81.226
Scheme 12 Proposed mechanisms of glutamate racemase inactivation
by 3-chloro-S-alanine 70S (b-chloro-S-alanine).
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approaches. The virtual screening study generated forty-nine
intermediate conformations en route from the ‘open’ to ‘closed’
conformations. Four of these conformations were used in
virtual screens of 31 000 compounds. These screens led to the
identification of covalent inhibitors (vide supra, Scheme 13),
which showed dose-dependent activity against T. cruzi in
infected mammalian cells.26,27
High-throughput screening and related approaches
High-throughput screening is an under-utilised approach to
discovering inhibitors of racemases and epimerases. High-
throughput screening offers a number of advantages, including
the possibility of discovering inhibitors which are not compe-
titive (which is the mode of inhibition often observed for active-
site-directed inhibitors).227
Several different in vitro assays have been used in discovery
campaigns. Release of tritium (3H+) from a radiolabelled sub-
strate into solvent was used in a screen of B5000 compounds
against human a-methylacyl-CoA racemase (AMACR).152
Crucially, the assay requires several steps, including chromato-
graphic separation of residual (acyl-CoA) substrate from tri-
tiated water product. Therefore, this assay is not ideally suited
for high-throughput or fragment-screening campaigns. This
study152 identified a number of non-specific protein-modi-
fying and degrading agents, such as ebselen, ebselen oxide
and Rose Bengal.127,152
A subsequent high-throughput screen on human AMACR163
made use of an eliminating substrate 37 (vide supra, Scheme 9)
producing 2,4-dinitrophenoxide 38.127 Conveniently, this allowed
identification of inhibitors based on absorbance changes over the
time course in a continuous assay. The screen identified a series
of mixed competitive and uncompetitive pyrazoloquinolines,
e.g. 85, and pyrazolopyrimidines, e.g. 86 (Fig. 15). The use of a
chromogenic substrate127 allows real-time monitoring of the
enzymatic reaction but substrates of this type can only be used
with a few racemases/epimerases.
Two studies have made use of high-throughput screens with
coupling enzymes. The first study, by Lundqvist et al., con-
ducted a high-throughput screen of 385 861 compounds
against H. pylori glutamate racemase.200 No details of the actual
screen are given but the authors used two different assays for
assessing identified inhibitor activity: conversion of S- to
R-glutamate was coupled to UDP-N-acetyl-muramic acid-
alanine: R-glutamate ligase (MurD) and purine nucleoside
phosphorylase with monitoring of the reaction at 360 nm.
In the second assay, conversion of R- to S-glutamate was
coupled to S-glutamate dehydrogenase with spectrophotometric
monitoring of conversion of NAD+ to NADH. These screens led to
the identification of an uncompetitive inhibitor (vide supra Fig. 12,
63), which was subsequently shown to exert its effect by changing
the conformation of the catalytic base, Cys-185, such that it points
away from the glutamate substrate Ca–H.
In a second example228 of a coupled assay, dTDP-6-deoxy-D-
xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC) was coupled
to the subsequent enzyme in the biosynthetic pathway, which is
NADP+-dependent, with activity being followed by decreasing
fluorescence of NADPH at 460 nm. This led to the identification
of a series of inhibitors, including some with potency in the nM
range e.g. 87 (Fig. 16).228 Use of coupling enzymes, such as in
these examples, is a standard approach in high-throughput and
fragment-screening campaigns227 (vide infra), although it is
always necessary to check if the hits are inhibiting the desired
target or the coupling enzyme.
Racemases used in biotechnological applications have been
assayed in several different ways, typically using oxidase
enzymes of various types. These assays could be adapted for
high-throughput screening for inhibitors. For example, mutant
mandelate racemases were assayed using mandelate dehydro-
genase, which uses NAD+. Conveniently, the ketoacid product
Fig. 15 Representative structures of pyrazoloquinoline and pyrazolo-
pyrimidine AMACR inhibitors.163 85a, R1 = R2 = H, uncompetitive inhibition,
Ki = 4.8  0.7 mM; 85b, R1 = R2 = F, mixed competitive inhibition,
Ki = 2.4  0.9 mM; 86, uncompetitive inhibition, Ki = 4.6  0.4 mM.
Fig. 16 Structure of the most potent hit 87 identified by high-throughput
screening inhibiting RmlC. 61 is a fully reversible, competitive inhibitor with
IC50 = 200 nM.
228
Fig. 14 Representative inhibitors of B. subtilis glutamate racemase iden-
tified using virtual high-throughput screening.23,24 The inhibitor ionisation
state shown are those that were used in the virtual screen.
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can be assayed using 2,4-dinitrophenylhydrazine (2,4-DNPH) at
alkaline pH with the final 2,4-dinitrophenylhydrazone product
absorbing at 450 nm.54 Ketoacids are also be produced by the
action of amino-acid racemases and epimerases on amino-acid
hydroxamate and other eliminating substrates82,128 (vide supra,
Schemes 3, 4, 6 and 7). Alternatively, the NAD(P)H product from
dehydrogenases can be assayed using diaphorases23,125 or by
direct monitoring of absorbance or fluorescence.
Similarly, hydrogen peroxide is produced by several oxida-
tive enzymes, including D-amino-acid oxidase, which can
be conveniently assayed using horseradish peroxidase.174,229
Notably, an assay based on D-amino-acid oxidase/horseradish
peroxidase was used to evaluate rationally designed inhibitors
of proline racemase26 and in the high-throughput screening
of alanine racemase.230 Similarly, a continuous assay for N-
acetylamino-acid racemases was developed using the R- sub-
strate 88R (Scheme 14).181 A stereoselective deacetylase was
used to convert the S- product 88S to the corresponding
S-amino acid 89S and acetate 90. L-Amino acid oxidase was
used to produce H2O2 from 89S, which was quantified by the
horseradish peroxidase-catalysed oxidation of dianisidine 90 to
give the coloured oxidation product 91.
In additional, several racemases/epimerases eliminate HF
from fluorine-containing substrates (vide supra, Scheme 8),120,121
which could potentially be assayed using fluoride sensors, although
this can be challenging in aqueous systems.161 Finally, microscale,
medium-throughput polarimetric assays offer the possibility of
direct observation of the change in chirality142 during screening.
Inhibitors of racemases and
epimerases
Racemases and epimerases play pivotal roles in metabolism
and are excellent drug targets. The following is a survey of
recent advances in drug development, focussing on recently
reported small-molecule inhibitors. Inhibition of many amino-
acid racemases/epimerases has been the subject of a recent
excellent review20 and readers are referred to this and the above
sections for details of studies on inhibition of diaminopimelate
racemase,20,124,217,218,226 proline racemase,26,27,135,188 hydroxy-
proline epimerase,20 aspartate racemase,20 serine racemase,188
isoleucine epimerase20 and O-ureidoserine racemase.46 Studies
on inhibition of mandelate racemase91,139,196–198,216 are
detailed in the section on inhibition strategies above. There
have been no reported studies on inhibition of EcL-DER, RacX,
YgeA, McyF, YcjG or N-acetylmannoseamine-6-phosphate
2-epimerase or N-acetylamino-acid or N-succinylamino-acid
racemases since 2015.
PLP-dependent racemases
Alanine racemase. Alanine racemase is involved in cyclo-
sporine biosynthesis179 and is a well-established antibacterial
drug target.18,20 The enzyme has been the subject of extensive
inhibitor studies,231,232 including the early studies with
3-fluoroalanine and 3-chloroalanine noted above.132 Other
inhibitors include several peptide and halogen-containing
peptides, phosphonic acid derivatives (fosfalin) and various
halovinylglycines and thiadiazolidinones.231,232
An important inhibitor of alanine racemase is D-cycloserine,
a natural product used in the treatment of drug resistant
tuberculosis.233,234 It is notable that the biosynthetic pathway
for D-cycloserine contains a reaction catalysed by a racemase,
O-ureidoserine racemase46 (vide supra, Scheme 10A). D-Cyclo-
serine 93 is a relatively non-specific antibiotic and targets
M. tuberculosis alanine racemase and D-Ala-D-Ala ligase.233,234
Inhibition of alanine racemase is proposed to occur by formation
of the external aldimine 94 followed by reversible rearrangement
to the ketimine 95 and isoxazole 96 (Scheme 15).233 Stereoselective
isotope exchange with solvent is observed when the reaction is
carried out in 2H2O, with D-cycloserine 93 incorporating deuter-
ium at the a-position without a change in stereochemical configu-
ration. Deuteration appears to arise by exchange of the a-proton.
Incubations of alanine racemase with D-cycloserine 93 also result
in the formation of isoxazole 97.233 The authors propose a
complex rearrangement of the keto tautomer of 96 but this seems
unlikely. A simpler explanation is that alanine racemase catalyses
hydrolysis of aldimine 94 using a hydrogen-bonded water mole-
cule, to form the linear aldimine 98 directly. This could undergo
imine exchange to form 99 but a more likely scenario is that 97 is
released from 98 which uses its hydroxylamine to form the
aldimine complex 99 directly (the pKa for the conjugate acid of
Scheme 14 Continuous assay of N-acetyl-amino acid racemases using a
three-enzyme coupling system to give a coloured product 92 absorbing at
436 nm.181
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the a-NH2 and g-O-NH2 groups are 9.14 and 3.16,
235 respectively,
and, hence, the g-O-NH2 group will be uncharged at neutral pH).
Thus, D-cycloserine 93 is both a substrate (undergoing a-proton
exchange and hydrolysis) and an irreversible inhibitor of alanine
racemase, consistent with the observation that M. tuberculosis
alanine racemase is not fully inhibited even by high concentra-
tions of 93.
A series of tetrazole-peptide derivatives were also designed
and synthesised as inhibitors of alanine racemase in bacterial
cells (Fig. 17).236 The tetrazole group is a well-established
bioisostere of the carboxylate group,236 and hence 5-(1-amino-
ethyl)tetrazole 100 should behave as an analogue of alanine.
S- and R-5-(1-aminoethyl)tetrazole 100 (AET) were inactive
when tested against a series of Gram-negative and -positive
bacteria236 but this is unsurprising as it is known that alanine
is imported into bacterial cells as an oligopeptide. Indeed,
fosfalin 101 is delivered to bacterial cells as a ‘‘dipeptide’’
alafosfalin 102.231,236
Therefore, a series of di- and tripeptide derivatives were
synthesised and tested.236 The SS-Ala-Ala analogue 103a was
active against several Gram-negative species, whilst the
SS-norvalene-AET 103b, SS-Leu-AET 103c and SS-Phe-AET
103d analogues were active against several Gram-positive
species. The SSS-Ala-Ala-AET analogue 104 showed similar
activity to 103a. N-Succinyl derivatives of these peptide analo-
gues were largely inactive. It was not determined if S- and R-5-
(1-aminoethyl)tetrazole 100 or any of the peptide analogues
were inhibitors of alanine racemase and hence the mechanism
of antibacterial activity has not been confirmed.
High-throughput screening of small-molecule and fungal
extract libraries against Aeromonas hydrophila alanine racemase
has also been performed. This screen identified several
previously unknown inhibitors (Fig. 18) of moderate potency
(IC50 = 6.6 to 18.5 mM), including homogentisic acid 105 and
hydroxyquinone 106.230 D-Cycloserine 93 (the control inhibitor)
had an IC50 of 5.4 mM under the conditions used in this screen.
Kinetic analysis showed that homogentisic acid 105 was a
competitive inhibitor (Ki = 51.7 mM) whilst hydroxyquinone
106 was a non-competitive inhibitor (Ki = 212 mM). These two
compounds showed antibacterial activity against A. hydrophila,
a Gram-negative anaerobic pathogen. Anabellamide 107 was a
potent inhibitor of alanine racemase in vitro (IC50 = 6.6 mM) but
was inactive in cellular assays (Fig. 18).
Scheme 15 Inhibition of alanine racemase by D-cycloserine 93. Note that
96 was proposed to be directly converted into 99233 but it is more likely
that 94 undergoes hydrolysis to form 98, which releases 97. This directly
forms two different external aldimines, 98 or 99, respectively (see text for
details).
Fig. 17 Structures of 5-(1-aminoethyl)tetrazole 100, fosfalin 101, alafos-
falin 102, and dipeptide analogues 103a-d and tripeptide analogue 104.236
Fig. 18 Structures of alanine racemase inhibitors identified by high-
throughput screening.230 Abbreviation used: Ph, phenyl.
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Isoleucine 2-epimerase. Isoleucine 2-epimerase is a novel
anti-bacterial drug target. There are only two studies on the
inhibition of isoleucine 2-epimerase.180,189 Mutaguchi et al.
noted, in their original characterisation of the enzyme, that it
was inhibited by non-specific inhibitors of other PLP-
dependent enzymes, such as hydroxylamine, aminooxyacetate
and phenylhydrazine.180 The effect of hydroxylamine was
reversed upon dialysis and addition of PLP to the buffer,
providing good evidence that the enzyme is a PLP-dependent
epimerase.
Subsequently, a study investigating inhibition of Lactobacillus
buchneri isoleucine 2-epimerase by substrate/product analogues
was reported.189 Two groups of inhibitors (Fig. 19) were investi-
gated, based on the structure of the substrate S-isoleucine 108.
These inhibitors fell into two classes: those with a single modified
sidechain (109–111); and those with dual sidechains (112), which
are similar to the substrate–product analogues that inhibit other
racemases and epimerases.139,149,150,174,188,197,198 The 2R- and
2S- enantiomers of 109 were substrates of the enzyme, although
these are converted with an efficiency of only B50% to 80% of
that of the natural substrates (as judged by kcat/Km values
180,189)
and, hence, would not be very effective competitive inhibitors.
On the other hand, 110 which possesses an additional methyl
group on the sidechain was not a substrate but instead behaved as
a pure competitive inhibitor (Ki values of 1.5 and 2.9 mM for the
2R and 2S enantiomers, respectively). Compound 111 which has
a cyclic sidechain was also an alternative substrate and was
converted with very similar efficiencies to 109 (as judged by
kcat/Km values). The synthesised compounds with dual sidechains
(112, n = 1, 2 and 3) were rather poor inhibitors, although potency
increased with increasing size and hydrophobicity of the side-
chain (Ki = 144, 19 and 11 mM, respectively).
Serine racemase. Serine racemase catalyses the formation
of R-serine from S-serine as well as the elimination of water.69
R-Serine binds to the N-methyl-D-aspartate (NMDA) receptor
glycine-binding site. The NMDA receptor is associated with
several neurological diseases, including Alzheimer’s disease,
amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s
disease, epilepsy and eye disease, amongst others, and psychiatric
diseases such as schizophrenia, and depression.35,237–241 Hence,
inhibition of serine racemase is of interest as a strategy for the
manipulation of levels of R-serine.
A large number of studies have appeared on the biological
and pathological role of serine racemase in the last five
years35,69,129,241–244 but only one study has reported synthesis
and evaluation of inhibitors.239 This study239 elaborated a
potent hit (Fig. 20, 113) identified in a previous virtual
screen.245 Of the synthesised compounds, five showed potent
inhibition of serine racemase in vitro. Two of these compounds
were similar in structure to the original hit and IC50 values were
determined for the three other compounds (140, 270 and
280 mM for 114, 115 and 116, respectively). This compares to
an IC50 value of 770 mM for malonate, a standard inhibitor.
Further studies showed 114 reduced NDMA receptor activation
by B1.4-fold, consistent with engagement of the target in vivo.
Cofactor-independent racemases and epimerases
Glutamate racemase (MurI). Glutamate racemase catalyses
the interconversion of S- and R-glutamate. R-Glutamate is a key
component of the bacterial cell wall17 and the enzyme is an
important drug target. Readers are also referred to the review
on amino-acid racemases20 and the previous section for details
of substrate/product analogues,175 allosteric inhibitors,21,25,200
covalent inhibitors,22–24,134 high-throughput screening200 and
virtual screening.23–25
Malapati et al. have reported a series of medium-throughput
screening studies on M. tuberculosis glutamate racemase using
thermal-shift assays (Fig. 21).246–248 Structure–activity relationship
(SAR) studies led to inhibitors 117–119 with low mM IC50 values.
Non-competitive inhibition was assigned based on the observed
changes within the thermal shift assay, although this was not
confirmed by enzyme activity assays. Docking studies suggested
that these compounds bound to an allosteric binding site.
In addition, Duvall et al. reported phenotypic screening of a
diversity-orientated synthetic collection (B100 000 compounds)
Fig. 19 structures of isoleucine 108 and inhibitors of isoleucine
2-epimerase.189 For 112, n = 1, 2 and 3.
Fig. 20 Structures of inhibitors of serine racemase.239,245
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against Clostridium difficile and other bacterial strains under
anaerobic conditions.249 One of the hits (BRD0761, Fig. 22, 120)
showed minimum inhibitory concentrations of 0.06–0.25 mg mL1
(0.13–0.55 mM) against various C. difficile strains, with much
higher MIC values against other anaerobes, while its epimer
BRD3141 121 was also active (Fig. 22). BRD0761 inhibited uptake
of [14C]-N-acetylglucosamine into bacteria in a dose-dependent
manner, suggesting that it targeted bacterial cell wall bio-
synthesis. The target was identified from resistance mutants
as glutamate racemase and a binding model was produced
based on the X-ray crystal structure of H. pylori enzyme. Dosing
of mice with 120 protected them from C. difficile infection.
UDP-N-acetylglucosamine 2-epimerase. UDP-N-acetylglucos-
amine 2-epimerase is one of the first enzymes in the teichoic
acid biosynthetic pathway,250 which is required for the integrity
of the bacterial cell wall. In addition, Zika virus uses 2,3-linked
sialic acid residues to enter mammalian cells and CRISPR-Cas9
knock-out of this enzyme reduces viral infection.251 The use of
N-acetylmannosamine analogues as inhibitors is especially
favourable, as N-acetylmannosamine is used solely for bio-
synthesis of sialic acid; in contrast, UDP-N-acetylglucosamine
is also used in the biosynthesis of other glycans252 and analo-
gues are likely to suffer from lack of selectivity.
A series of N-acetylglucosamines and N-acetylmannos-
amines, some with modified UDP moieties, have been pre-
viously developed as inhibitors but had modest potency
(reviewed in ref. 253). Nieto-Garcia et al., reported a series of
inhibitors in which the C6 hydroxy group was replaced with
sulfur or selenium (Fig. 23).253 The diselenide inhibitor 122
proved to be highly potent (IC50 = 8.5 mM) compared to the
other inhibitors (IC50 values of 1.9 to 410 mM). The dimeric
monoselenide inhibitor 123 was much less potent (IC50 = 3.0 mM).
The corresponding disulfide analogue 124 was also much less
active than 122 (IC50 = 4.2 mM), showing the importance of the
diselenide unit for potent inhibition. The much higher potency of
122 compared to the other inhibitors could be due to bond length
or flexibility of the linker.253 Small-molecule diselenide bonds have
been reported as having a bond length of 2.29 Å,254 while disulfide
bonds (in proteins) have a corresponding bond length of 2.05 Å.255
It has also been suggested that van der Waals interactions and
hydrogen bonding potential may also be important in determining
inhibitory potency.253 Diselenide 122 was a competitive inhibitor
with a Ki value of 15.7 mM.
253
Hinderlich et al. reported a high-throughput screening
campaign using a library of 41 536 compounds and a luciferase
assay to measure ATP depletion.252 The N-acetylmannosamine
substrate was used at 33 mM, close to its Km value, with an
average Z0 value (a measure of the ability of the assay to
discriminate between a hit and random noise227,256) of 0.78.
Compounds were screened at 13 mM, yielding 252 hits of which
174 were analysed using dose–response curves, yielding 46
inhibitors with IC50 o 33 mM. Further analysis and counter-
screening against yeast hexokinase yielded several leads 125–
128 (Fig. 24). The IC50 values did not significantly change with
changing concentrations of ATP, suggesting that they were non-
competitive. Modelling studies suggested that 125, 126 and 128
bound in the N-acetylmannosamine-binding site in the closed
form of the enzyme, although 127 was larger than the available
site, suggesting it might be bound to the open conformation.252
Fig. 22 Structures of BRD0761 120 and BRD3141 121.249
Fig. 23 Structures of (di)selenide and disulfide inhibitors of UDP-N-
acetylglucosamine 2-epimerase/N-acetylmannosamine kinase.253
Fig. 24 Structures of UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase inhibitors.252
Fig. 21 Structures of leads reported by Malapati et al.246–248
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UDP-N-acetylglucosamine epimerase/N-acetylmannosamine
kinase is also one of only two racemases or epimerases to be
subjected to a fragment-screening campaign.257 A library of 281
fluorinated fragments were screened at 50 mM using 19F NMR
and binding of inhibitor was confirmed by competition with
N-acetylmannosamine and ATP, yielding 23 hits. Of these,
compound 129 was also shown to inhibit in a coupled enzyme
assay and so was chosen for development. Analogues of 129
were screened, leading to identification of 130 which was
optimised to 131 (Fig. 25). Modelling of the binding of the
inhibitor suggested that 131 bound to the active-site Mg2+ used
in the kinase reaction, near the catalytic site. However, these
compounds were not developed into more potent leads.
dTDP-4-keto-6-deoxyglucose 3,5-epimerase (RmlC). dTDP-4-
keto-6-deoxyglucose 3,5-epimerase (RmlC) is involved in bio-
synthesis of L-rhamnose in M. tuberculosis and other
bacteria.111,228 L-Rhamnose is biosynthesised from D-glucose-
6-phosphate in a four-step pathway. The third step of this
pathway is epimerisation at both carbons C3 and C5 of the
4-ketosugar moiety catalysed by RmlC, followed by reduction
of the keto group by RmlD in the final step.111 Because
L-Rhamnose is essential for the integrity of the bacterial cell
wall, RmlC and the other enzymes in the pathway are drug
targets.258–260 RmlC is also responsible for activation of the
virulence factor in the marine pathogen Vibrio vulnificus.261
Several inhibitors of RmlC have been previously charac-
terised (including the high-throughput screening inhibitors
noted above;228 vide supra, Fig. 16), although many have limited
aqueous solubility.259 van der Beek et al. conducted a fragment-
screening campaign with a commercial library using bio-layer
interferometry.259 A library of B1000 fragments was screened
at 200 mM with twelve hits. Of these, seven compounds showed
dose-dependent enzyme inhibition and inhibited bacterial
growth. Three hits (Fig. 26, 132–134) with diverse structures
inhibited both RmlB (the preceding enzyme in the biosynthetic
pathway) and RmlC.
Sasikala et al. also conducted a virtual screen of RmlC and
identified several potential inhibitors of the Vibrio vulnificus
enzyme (also known as WbpP).261 However, none of these
compounds were confirmed as hits in biochemical or bio-
physical screens.
a-Methylacyl-CoA racemase. a-Methylacyl-CoA racemase
(AMACR; P504S) is a metabolic enzyme involved in the degra-
dation of branched-chain fatty acids and the activation of
ibuprofen and related drugs.6,7 Levels of the AMACR protein
are increased in prostate cancer and many other cancers and
the reader is referred to previous reviews on the subject.6,7 The
M9V single-nucleotide polymorphism (SNP) is well known to
increase risk of prostate cancer (reviewed in ref. 7) but recent
analysis showed interaction of this SNP with SNPs in serine/
threonine kinase AKT1 which are also involved in prostate
cancer.262 Levels of AMACR protein have also been shown to
be downregulated by microRNA miR200, resulting in decreased
proliferation and migration of prostate cancer cells.263 Inter-
estingly, a recent epidemiological study showed that AMACR
levels were diminished in men with prostate cancer who
supplemented their diet with extracts from cruciferous vegeta-
bles, such as broccoli, which contains the isothiocyanate com-
pound, sulforaphane.264 AMACR levels are also increased in
glioblastoma265,266 and high AMACR levels are correlated with
poor prognosis for patients.265 Hence, AMACR is a potentially
a novel biomarker for glioblastoma.265 siRNA knock-down of
AMACR levels led to reduced proliferation of glioblastoma
cells.265 Increased AMACR levels are thought to indicate an
increase in fatty acid b-oxidation, in a similar way to that
observed in prostate cancer.266
AMACR has been the subject of several previous inhibitor
studies as well as structural studies on the M. tuberculosis
homologue (MCR), with literature up to the end of 2012 having
been previously reviewed.6,7 Following on from previous
reports,136 Carnell et al. reported a series of acyl-CoA inhibitors
with modified cores.191 The reported several new inhibitors
(Fig. 27) including ()-a-fluoroibuprofenoyl-CoA 49 (in which
the Ca–H was replaced by fluorine), a chloro derivative 135, and
N-dodecanoyl-R-alanyl-CoA 136. Inhibitor 49 replaces the Ca–H
with a Ca-F, effectively removing the a-proton. Substitution of
Fig. 25 Structure of hit 129 and derived inhibitors 130 and 131.257
Fig. 26 Structures of fragment screening hits active against RmlC.259
Fig. 27 Structures of rationally designed AMACR inhibitors reported by
Carnell et al.191
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hydrogen with fluorine is commonly used in drug design
because of the similar atomic radii (1.10 vs. 1.35 Å),267 bond
lengths to carbon (1.08 to 1.11 vs. 1.26 to 1.41 Å)267 and the high
C-F bond energies (typically 4456 kJ mol1).138,268 Inhibitors
135 and 136 are expected to form the enolate intermediate
more easily,191 although this was not actually proven. Model
studies suggest the Ca–H pKa for 136 should be B14.5–
16.586,191 compared to a Ca–H pKa of B21 for standard acyl-CoA
esters.86,88 Inhibitors 49 and 135 had IC50 values of 324 and
570 nM.191 N-Dodecanoyl-R-alanyl-CoA 136 was less potent,
with an IC50 value of 2300 nM, which is probably be due to
lower stabilisation of the negatively charged intermediate.191
The known inhibitor ()-2-trifluoromethyltetradecanoyl-CoA136
47 had an IC50 of 156 nM.
191 Significantly, two potent carba-
mate inhibitors 56 and 137 as analogues of the intermediate
enolate were reported (IC50 = 98 and 1000 nM). Later
studies127,164 showed that the carbamate inhibitor 56 was
highly potent compared to other inhibitors (IC50 = B0.4 nM
using the colorimetric assay127).
Also following on from the Carnell et al. study in 2007,136
Festuccia et al.190 reported the synthesis and testing of
trifluoroibuprofenoyl-CoA (Fig. 28, 48). Limited kinetic analysis
suggested non-competitive inhibition by this compound with a
Ki = 1.7 mM. This result is notable because non-competitive
inhibition of enzymes is rather rare (reviewed in ref. 227) and
this is the only example of a non-competitive inhibitor reported
for AMACR (and one of only a few for racemases/epimerases in
general). Non-competitive inhibition is inconsistent with the
inhibitor acting as an alternative substrate but instead arises
through allosteric inhibition, stabilisation of an inactive con-
formation or covalent modification of the target.227 The basis
for inhibition of AMACR by trifluoroibuprofenoyl-CoA is
unclear, although elimination of fluoride is not reported.
Treatment of cultured androgen-dependent and -independent
prostate cancer cells with the pro-drug trifluoroibuprofen
(Fig. 28, 138) resulted in arrest at G2/M in the cell cycle and a
host of other changes, including induction of apoptosis.190
Tumour growth in androgen-dependent and -independent
prostate cancer xenograft mouse models was also significantly
reduced by treatment with this agent.190
The advent of the AMACR colorimetric assay (vide supra,
Scheme 9)127 has enabled much more thorough testing of
inhibitors than had been previously possible, including deter-
mination of IC50 and Ki values and of reversibility of inhibition.
This also enabled the first structure–activity relationship stu-
dies to be conducted. The first studies127,164 looked at a series
of known AMACR inhibitors and substrates. A second study165
looked at a focussed series of 2-(arylthio)propanoyl-CoA inhibitors;
the presence of the side-chain sulfur atom resulted in increased
acidity of the Ca–H (previous studies on straight-chain acyl-CoAs
and their 3-thia analogues showed that the presence of the sulfur
reduces the pKa of the Ca–H to B15–16.5,
269,270 compared to B21
for the corresponding acyl-CoA86,88). Many of these 2-(arylthio)-
propanoyl-CoA inhibitors were equipotent to fenoprofenoyl-CoA
but optimisation of the inhibitor side-chain resulted in increased
potency, e.g. 139, IC50 = 22.3 nM.
165 A 2-(arylsulfonyl)propanoyl-CoA
inhibitor 140 was also synthesised in the hope that the presence of
the sulfonyl group would further increase Ca–H acidity but this
proved to be a poor inhibitor (Fig. 29).165
Plotting pIC50 values for all inhibitors
127,164,165 characterised
by the AMACR colorimetric assay127 against calculated log P
values (Fig. 30) showed that inhibitor potency was positively
correlated with log P. The 2-(arylsulfonyl)propanoyl-CoA inhibi-
tor 140 was highly hydrophilic,165 suggesting that this was
the reason for its unexpected low potency. Although the
2-(arylthio)propanoyl-CoA inhibitors, such as 139, were highly
potent in enzyme assays in vitro (IC50 = 22–520 nM), the
carboxylic acid pro-drugs did not show any appreciable inhibi-
tion of androgen-dependent or -independent prostate cancer
cells,165 possibly due to oxidation of the inhibitor pro-drug
sulfur to the sulfoxide or sulfone.
Since the last review,7 two studies featuring rational design
of inhibitors for the M. tuberculosis AMACR homologue, MCR,
have been published. The first study149 describes the synthesis
and testing of several substrate/product acyl-CoA inhibitors
Fig. 28 Structures of trifluoroibuprofenoyl-CoA 48 and the trifluoro-
ibuprofen pro-drug 138.190
Fig. 29 Structure of the most potent 2-(arylthio)propanoyl-CoA inhibitor 139
and the poorly active 2-(arylsulfonyl)propanoyl-CoA 140 of human AMACR.165
Fig. 30 Potency of acyl-CoA inhibitors of AMACR, as measured by
pIC50 as a function of calculated log P values. Inhibitors are as follows
(with compound numbers from the original papers in parentheses):
Ibuprofenoyl-CoA and analogues (5–11);164 straight-chain acyl-CoAs and
other substrates (12–14 and 18–21);164 inhibitors with modified acyl-CoA
cores (4, 22–26);164 and 2-arylthiapropanoyl-CoAs and 2-arylsulfonyl-
propanoyl-CoA (7a–7n, 10b).165 Log P values were calculated using:
https://www.molinspiration.com/cgi-bin/properties. Log P, log10 (ratio of
concentrations of drug in octan-1-ol and water at equilibrium); pIC50,
log10IC50.
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(vide supra), in which the a-proton is replaced by a second side-
chain in the inhibitor. The presence of the second sidechain
increases potency of inhibition by B6-fold, although the mea-
sured absolute potency is relatively modest (e.g. 16.9 cf. 106 mM
for 45a vs. ibuprofenoyl-CoA). One of these inhibitors (Fig. 31A,
45b) has a a-proton in place of the a-methyl group and, as
predicted, this does not undergo enzyme-catalysed exchange with
solvent consistent with the a-proton being located in the methyl-
binding site of the enzyme. The study is also notable in that
several carboxylic acid precursors are also inhibitors, albeit with
IC50 values in the mM range.
149 Similar to the above AMACR
inhibitors (vide supra, Fig. 30), potency of inhibition of MCR is
also related to calculated log P values (Fig. 31).
Following from the observation that carbamate analogues
are highly potent AMACR inhibitors,127,164,191 Pal et al.150
synthesised and tested carbamate analogues 141–144 of
their substrate/product inhibitors against MCR (Fig. 31A).149
Inhibition is reported to be competitive, although the Line-
weaver–Burk plots for some analogues, e.g. 143 (n = 5),
suggested mixed competitive inhibition. Surprisingly, several
of these analogues show irreversible inhibition, in marked
contrast to the carbamate AMACR inhibitors which are fully
reversible.127,164 Inhibitors with long alkyl chains (n = 9 and 11)
show saturating loss of activity with maximum kinact values of
B0.4 min1 consistent with being active-site directed. Analo-
gues with less lipophilic side-chains (143, n = 3) or a single side-
chain (144) showed a non-saturating loss of enzymatic activity
with a rate constant of 0.016–0.04 min1.150 Inhibition was not
reversed upon dialysis but no protein modification was
observed by mass spectrometry. This observation is consistent
with either non-covalent slow-binding inhibition, resulting in a
long-lived enzyme-inhibitor complex, or irreversible inhibition
resulting in a covalent modification of the protein, which is
labile under mass spectrometric conditions.
Identification of AMACR inhibitors by high-throughput
screening has also been reported.163 Unlike the previous
study,152 the identified inhibitors were not non-specific protein
modification agents.163 A number of pyrazoloquinolines and
pyrazolopyrimidines were identified (vide supra, Fig. 15, 85a,
85b and 86), and some structure–activity relationships were
observed.163 The identified inhibitors displayed either mixed
competitive or uncompetitive inhibition. The latter is a rare
type of inhibition and arises from binding of inhibitor to the
enzyme-substrate complex.
Conclusions
Racemases and epimerases occupy a unique position in meta-
bolism, in that they are the only major class of enzymes which
can use substrates with both configurations at a chiral centre.
Because of this, many racemases and epimerases are excellent
drug targets and several have been extensively investigated as
such, e.g. glutamate racemase.20–25,134,175,200,249 Use of inhibi-
tors with the same configuration as the less abundant substrate
(often D- or R-enantiomer) potentially offers additional benefits
in that these isomers may be less prone to off-target binding
and may have reduced drug metabolism, with consequent
reductions in toxicities and longer durations of action.
However, efforts to develop drugs targeted against race-
mases and epimerases have been largely limited to rational
design campaigns, with the few notable exceptions detailed
above. Development of inhibitors which are alternative sub-
strates has met with limited success, in part because several of
the effective inhibitors are rapidly depleted in vivo whilst the
effects of less effective inhibitors are readily overcome by the
physiological substrate. Moreover, these inhibitors are neces-
sarily chiral and there had been a move away from chiral drugs
towards drugs with fewer sp3 carbons.227 This is despite a
growing realisation that the attrition rate is higher for ‘flatter’
drugs271,272 and that licenced drugs have a higher average
proportion of sp3 centres than molecules published in The
Journal of Medicinal Chemistry.273 Consequently there has been
a more recent move towards structures with a higher proportion
of sp3 and chiral centres.274 Similarly, racemase/epimerase
Fig. 31 (A) Structures of substrate–product analogues149,150 inhibiting the
M. tuberculosis homologue of AMACR (MCR). For 143, n = 3, 5, 7, 9 or 11;
(B) acyl-CoA inhibitor potency as measured by pIC50 as a function of
calculated Log P values. Log P values were calculated using: https://www.
molinspiration.com/cgi-bin/properties. Log P, log10 (ratio of concentrations
of drug in octan-1-ol and water at equilibrium); pIC50, log10IC50.
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inhibitors in which the Ca–H is replaced or where deprotonation
is made more difficult tend not to be highly potent. The use of
substrate–product analogues as inhibitors has also met with
variable success. This strategy tends to work relatively well for
racemases and epimerases in which large changes in substrate
side-chain position occur during the reaction. Enzymes catalysing
reactions resulting in limited changes in side-chain position and/
or with small or sterically hindered active sites tend to be poorly
inhibited by this type of compound.
There are relatively few developed inhibitors which are
analogues of the transition state/deprotonated intermediate,
perhaps because the early inhibitors developed against proline
racemase were not highly effective and one of these inhibitors
was an unstable imine.135 Some covalent inhibitors have been
developed by rational design or identified by screening
techniques.20,22–24,26,27,46,124,134,217,218 There has been renewed
interest in the development of covalent inhibitors in recent
years, prompted by a number of covalent drugs coming into
clinical use.201,205,207,208 Covalent drugs acting on racemases
and epimerases have all been directed against enzymes using
active-site cysteine thiols20,22–24,26,27,46,124,134,217,218 (amino-acid
racemases and epimerases). Covalently reacting drugs contain-
ing electrophiles reacting with other active-site bases205,208 have
been under-explored. Both transition-state analogues135,193,194
and covalent inhibitors201,204–206,208 offer the potential for high
potency and long duration of action and are potentially fertile
ground for the future development of inhibitors.
Screening approaches227 have also been under-used to iden-
tify novel inhibitors. There are only five high-throughput
screening campaigns in the literature152,163,200,228,252 and only
two fragment-screening campaigns.257,259 Almost all racemases
and epimerases catalyse reversible reactions and this places
restriction on these assays but these can be overcome by using
an elimination substrate or irreversible coupling enzyme (see
section on enzyme assays for examples). The use of coupling
enzymes also enables assays based on fluorescence or absor-
bance to be used, which are readily adaptable to high-
throughput screening formats.227 Direct assaying of racemase
or epimerase activity may also be possible using fluorescence
anisotropy to monitor ligand binding.227
Fragment screening using assays of enzyme activity227,275–279
or biophysical techniques275–280 (particularly X-ray crystallo-
graphy274–277,279–281) hold significant promise, although the
different screening techniques have advantages and
disadvantages280 and different tendencies towards false posi-
tive and negative results.279 There is also a balance to be struck
between fragment complexity and affinity to maximise chances
of success.279 Screening of fragment libraries for direct identifi-
cation of inhibitors is particularly appealing for enzymes
with small, enclosed active sites, e.g. proline racemase,26,27 as
the amino-acid substrates are small fragments themselves
(Mw = 89–204 Da). There have been a number of studies on
the screening of small fragments (which will generally have
low affinity279), including one using virtual screening initially
to triage compounds which resulted in a 40% hit rate for a very
small fragment library (fifteen compounds).282 Similarly,
fragment-based screening holds promise for development of
inhibitors of enzymes with larger active sites,227,275–280 although
there are challenges associated with identification of different
fragments which bind simultaneously and also in the elaboration
of fragment hits into leads.274,283
It is important that inhibitors produced by rational design,
identified by screening and other approaches are fully charac-
terised to determine if covalent modification of the target is
occurring. There are examples of rationally designed racemase
inhibitors intended to be reversible which appear to exert their
effects by covalent modification of the racemase target.150
Several inhibitors identified by screening approaches239,252,259
could also potentially inhibit their targets by covalent modification.
Unselective modification of off-target proteins or other biological
molecules could give rise to significant toxicities.201–205,207–209,215
Therefore, it is important to balance this potential draw-back with
the advantages of covalent inhibition.
Abbreviations used
AET 5-(1-Aminoethyl)tetrazole
AMACR Human a-methylacyl-CoA racemase
(a.k.a. P504S) spliced variant 1A
DprE Decaprenylphosphoryl-b-D-ribose epimerase
EcL-DER E. coli L-aspartate/L-glutamate racemase
IAM 12614 L. aggregata cis-3-hydroxy-S-proline racemase/
dehydratase
MCR a-Methylacyl-CoA racemase from M. tuberculosis
McyF Microcystis aeruginosa aspartate racemase









YgeA E. coli homoserine racemase
YcjG E. coli alanyl dipeptide epimerase.
Standard one- and three-letter amino-acid codes
are used.
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